Key findings on prostate cancer treatment from the 2025 ASCO meeting are reported by Dr Oliver Sartor from Tulane Medical School in New Orleans. Next, Dr Sartor discusses a phase 1/2 study of ...

Studies presented at the ASCO Annual Meeting 2025 highlighted immunotherapies that may provide new standards of care for certain cancers as well as immunotherapies that are breaking new ground by ...

T cell therapy, zilovertamab vedotin in relapsed or refractory (R/R) LBCL, and optimal dosing of AFM13 plus AlloNK in R/R ...

The panel discussion at the "Breathtaking Moments" event during ASCO weekend. (Johnson & Johnson) Swarner led a discussion with lung cancer survivor Maggie McCloskey, patient advocate and podcast ...

ASCO’s bubble of hope: Execs focus on ‘rewriting textbooks’ in cancer care at conference By Gabrielle Masson Jun 2, 2025 9:45am ASCO 2025 ASCO Takeda Takeda Oncology ...

ASCO: Vepdegestrant ups survival in ER+, HER2− advanced breast cancer with ESR1 mutations. Your friend's email. Your email. I would like to subscribe to Science X Newsletter. Learn more.

By attending ASCO, he said marketers can interface with key stakeholders, understand their perspectives and craft communications strategies accordingly. As it relates to the growing influence of ...

WHIPPANY, N.J., May 28, 2025--ASCO 2025: XOFIGO® Combination Data Showcases Clinical Benefits in Metastatic Castration-Resistant Prostate Cancer with Bone Metastases ...

FOSTER CITY, Calif., May 28, 2025--Geron announces presentations on RYTELO® (imetelstat) at 2025 ASCO Annual Meeting and EHA 2025 Congress.

ASCO: GLP-1 receptor agonists may reduce risk for obesity-related cancer, all-cause death. Your friend's email. Your email. I would like to subscribe to Science X Newsletter. Learn more.

During the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting press briefing on May 21, 2025, there were 4 significant abstracts presented, highlighting practice-shaping data for ...

Itovebi, when added to Pfizer’s Ibrance and AstraZeneca’s Faslodex, cut the risk of death by 33% in certain HR+/HER2- breast cancer patients.